Semaglutide Side Effects: Safety & Regulatory Status
Semaglutide can cause nausea, vomiting, and more serious risks. Learn what the evidence says about its side effects and how it's regulated before talking to a physician.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to manage type 2 diabetes. It mimics a hormone your gut naturally releases after eating, signaling the pancreas to produce insulin, slowing gastric emptying, and reducing appetite. The FDA has approved semaglutide under the brand names Ozempic (injectable, for diabetes), Wegovy (injectable, for chronic weight management), and Rybelsus (oral tablet, for diabetes).
Because demand for the branded versions has far outpaced supply in recent years, compounded semaglutide — mixed by licensed compounding pharmacies — became widely available through telehealth clinics. The FDA has noted concerns about compounded versions and advises patients to understand the difference between FDA-approved products and compounded alternatives, which do not undergo the same pre-market review process.
Common Side Effects
Most side effects cluster around the gastrointestinal (GI) system. They tend to be most pronounced when starting the medication or moving to a higher dose, then ease over time for many patients.
Frequent GI complaints include:
- Nausea (the most commonly reported effect — affects a significant portion of users)
- Vomiting
- Diarrhea or constipation
- Abdominal pain or discomfort
- Bloating and belching
- Reduced appetite (desired for weight-loss use, but can become excessive)
These effects are generally dose-dependent. Clinics typically manage them with a slow titration schedule — starting at a low dose and gradually increasing over several weeks.
Other relatively common effects:
- Fatigue, particularly early in treatment
- Headache
- Dizziness
- Injection-site reactions (redness, swelling, or itching) with the injectable forms
Serious Risks to Know
The more serious potential risks are less common but important to understand before starting therapy. The FDA prescribing information for semaglutide products includes the following warnings:
Thyroid C-cell tumors: In rodent studies, GLP-1 receptor agonists caused thyroid C-cell tumors. Whether this risk applies to humans is not yet established, but semaglutide carries a boxed warning — the FDA's most serious label warning — for this possibility. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use semaglutide.
Pancreatitis: There have been postmarketing reports of acute pancreatitis in patients using GLP-1 agonists. Symptoms like severe, persistent abdominal pain — sometimes radiating to the back — should be evaluated immediately. Patients with a history of pancreatitis should discuss this risk carefully with their physician.
Gallbladder disease: Rapid weight loss of any kind increases the risk of gallstones. Clinical trial data for semaglutide showed a higher rate of gallbladder-related events compared to placebo. Mayo Clinic lists gallbladder problems as a recognized risk with GLP-1 therapies.
Hypoglycemia: On its own, semaglutide carries a low risk of low blood sugar. However, combining it with insulin or sulfonylureas significantly raises that risk.
Kidney injury: Severe GI side effects can lead to dehydration, which in turn may worsen kidney function, particularly in people who already have kidney disease.
Heart rate increase: A modest increase in resting heart rate has been documented in trials. While the cardiovascular outcomes data for semaglutide are actually favorable in diabetic populations with established heart disease, anyone with arrhythmias should flag this with their provider.
Suicidal ideation: The FDA has investigated reports of suicidal thoughts linked to GLP-1 agonists. As of its most recent communications, the agency has not established a definitive causal link, but monitoring continues. Patients with a history of depression or suicidal ideation should discuss this with their physician.
Who Should Avoid Semaglutide?
Certain individuals should not use semaglutide at all:
- Personal or family history of MTC or MEN 2
- Known hypersensitivity to semaglutide or any inactive ingredients
- Pregnancy (weight-loss use is not recommended; patients should stop semaglutide at least two months before planned conception)
- Active pancreatitis
Compounded Semaglutide: A Different Conversation
When demand outstripped supply of brand-name products, the FDA permitted compounding pharmacies to produce semaglutide under specific shortage rules. That shortage designation has since been updated, and the FDA has issued guidance indicating that the shortage has been resolved for some formulations — meaning compounded versions may no longer qualify for the same regulatory allowances.
Some compounded formulations have also included semaglutide salts (such as semaglutide sodium or acetate) rather than the base form used in approved products. The FDA has flagged these as distinct, unapproved substances. Patients considering compounded semaglutide should ask their prescribing clinic specifically which form they are receiving and verify that the compounding pharmacy holds proper state licensure and follows USP standards.
Practical Takeaways for Patients
- GI side effects are expected, especially early. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help reduce their severity.
- Report serious symptoms promptly. Severe abdominal pain, signs of an allergic reaction (swelling of the face or throat, difficulty breathing), or changes in mood warrant immediate medical attention.
- Not all semaglutide products are the same. FDA-approved branded products differ from compounded versions in terms of regulatory oversight, purity verification, and legal status.
- A physician's oversight matters throughout. Semaglutide is not an over-the-counter supplement. Ongoing monitoring of labs, kidney function, and overall response is part of responsible use.
Regulatory Status Summary
| Product | FDA Status | Indication |
|---|---|---|
| Ozempic | FDA-approved | Type 2 diabetes |
| Wegovy | FDA-approved | Chronic weight management |
| Rybelsus | FDA-approved | Type 2 diabetes (oral) |
| Compounded semaglutide | Not FDA-approved; status evolving | Varies by clinic |
Always consult a licensed physician before starting, adjusting, or stopping semaglutide or any related therapy.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider for guidance specific to your health situation.